Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxia-mediated oxidative damage.
Obstructive sleep apnea (OSA) syndrome has been recognized as a highly prevalent public health problem and is associated with major neurobehavioral morbidity. Chronic intermittent hypoxia (CIH), a major pathological component of OSA, increases oxidative damage to the brain cortex and decreases neurocognitive function in rodent models resembling human OSA. We employed in vitro and in vivo approaches to identify the specific phases and subcellular compartments in which enhanced reactive oxygen species (ROS) are generated during CIH. In addition, we utilized the cell culture and animal models to analyze the consequences of enhanced production of ROS on cortical neuronal cell damage and neurocognitive dysfunction. In a primary cortical neuron culture system, we demonstrated that the transition phase from hypoxia to normoxia (NOX) during CIH generates more ROS than the transition phase from NOX to hypoxia or hypoxia alone, all of which generate more ROS than NOX. Using selective inhibitors of the major pathways underlying ROS generation in the cell membrane, cytosol, and mitochondria, we showed that the mitochondria are the predominant source of enhanced ROS generation during CIH in mouse cortical neuronal cells. Furthermore, in both cell culture and transgenic mice, we demonstrated that overexpression of MnSOD-decreased CIH-mediated cortical neuronal apoptosis, and reduced spatial learning deficits measured with the Morris water maze assay. Together, the data from the in vitro and in vivo experiments indicate that CIH-mediated mitochondrial oxidative stress may play a major role in the neuronal cell loss and neurocognitive dysfunction in OSA. Thus, therapeutic strategies aiming at reducing ROS generation from mitochondria may improve the neurobehavioral morbidity in OSA.
Shan
Xiaoyang
X
Department of Anatomy and Cell Biology, University of North Dakota School of Medicine, Grand Forks, ND 58202, USA.
Chi
Liying
L
Ke
Yan
Y
Luo
Chun
C
Qian
Steven
S
Gozal
David
D
Liu
Rugao
R
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000187:drug effects / Q000201:enzymology* / Q000503:physiopathology; D002908:Chronic Disease; D004195:Disease Models, Animal; D015971:Gene Expression Regulation, Enzymologic / Q000235:genetics; D002534:Hypoxia, Brain / Q000201:enzymology* / Q000235:genetics / Q000503:physiopathology; D007859:Learning Disabilities / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D009474:Neurons / Q000187:drug effects / Q000201:enzymology*; D018384:Oxidative Stress / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D020181:Sleep Apnea, Obstructive / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism*
D017382:Reactive Oxygen Species; D013482:Superoxide Dismutase
Sleep. 1995 Jan;18(1):43-52
7761742
Eur Respir J. 2006 May;27(5):997-1002
16707395
Chest. 1996 Apr;109(4):916-21
8635370
J Neurosci Res. 1996 May 1;44(3):293-9
8723768
J Clin Invest. 1996 Sep 1;98(5):1253-60
8787689
Arzneimittelforschung. 1998 Jun;48(6):629-36
9689418
Arch Biochem Biophys. 1999 Feb 1;362(1):59-66
9917329
Trends Neurosci. 1999 Feb;22(2):47-51
10092042
Free Radic Biol Med. 2000 Apr 15;28(8):1197-205
10889449
Methods Mol Biol. 2000;99:15-24
10909073
Eur Respir J. 2000 Oct;16(4):644-7
11106206
J Neurosci. 2001 Apr 1;21(7):2442-50
11264318
Am J Respir Crit Care Med. 2001 Apr;163(5):1181-90
11316657
J Appl Physiol (1985). 2001 Dec;91(6):2758-66
11717244
J Sleep Res. 2002 Mar;11(1):1-16
11869421
Arch Intern Med. 2002 Apr 22;162(8):893-900
11966340
Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39
11991871
Acta Neuropathol. 2002 Aug;104(2):113-22
12111353
Am J Respir Crit Care Med. 2002 Nov 15;166(10):1382-7
12421746
Sleep Med Rev. 2003 Feb;7(1):35-51
12586529
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1548-53
12615622
J Neurochem. 2003 Sep;86(6):1545-52
12950463
Chest. 2003 Oct;124(4):1386-92
14555570
Sleep. 2004 Feb 1;27(1):123-8
14998248
Pediatr Pulmonol Suppl. 2004;26:166-8
15029640
Sleep. 2004 Mar 15;27(2):194-201
15124711
Biol Chem. 2004 Mar-Apr;385(3-4):217-21
15134334
Neuroscience. 2004;126(2):313-23
15207349
J Neurosci Methods. 1984 May;11(1):47-60
6471907
Anal Biochem. 1987 Mar;161(2):245-57
2883911
Proc Natl Acad Sci U S A. 1990 Jul;87(13):5144-7
1973301
Free Radic Res Commun. 1990;10(1-2):11-5
2165980
Methods Enzymol. 1994;233:346-57
8015469
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1587-91
7952619
J Card Fail. 2005 Aug;11(6):437-46
16105635
Am J Respir Crit Care Med. 2005 Oct 1;172(7):921-9
15994465
Am J Respir Crit Care Med. 2005 Oct 15;172(8):1056-7; author reply 1057-8
16216840
Neurol Clin. 2005 Nov;23(4):1059-75
16243616
Eur Heart J. 2005 Nov;26(22):2435-9
16105851
J Biol Chem. 2005 Nov 11;280(45):37339-48
16150735
Sleep Med. 2006 Jan;7(1):7-16
16309961
Respir Physiol Neurobiol. 2006 Mar 28;151(1):44-60
15993658
Am J Respir Cell Mol Biol. 2006 Apr;34(4):505-13
16357364
Am J Respir Crit Care Med. 2006 Apr 15;173(8):897-901
16439717
Novartis Found Symp. 2006;272:95-9; discussion 100-5, 131-40
16686431
J Neurosci Res. 1995 Dec;42(5):674-83
8600300